Regeneron Pharma: FDA Grants Approval For Otarmeni, Gene Therapy For Genetic Hearing Loss

AI Briefing

• – Regeneron Pharma granted FDA approval for Otarmeni, a gene therapy for genetic hearing loss.
• – Otarmeni is the first gene therapy and second new molecular entity approved under the FDA's accelerated approval process.
• – Regeneron Pharmaceuticals is developing Otarmeni to treat genetic hearing loss in certain individuals.